Skip to main content

Table 1 Comparison of baseline characteristics between both treatment arms

From: A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study

  Vancomycin (n = 7) Daptomycin (n = 7) All (n = 14)
Age in years (median, IQR) 70 (64, 71) 65 (50, 71) 67.5 (54.5, 71)
Age > 65 years 4 3 7
Gender    
Male 5 5 10
Female 2 2 4
Ethnicity    
Chinese 4 6 10
Malay 1 0 1
Indian 1 1 2
Others 1 0 1
Charlson comorbidity score (median, IQR) 5 (4, 7) 5 (4, 8) 5 (4, 7)
Diabetes mellitus prior to screening 0 2 2
CKD prior to screening 3 2 5
Diabetes mellitus and CKD prior to screening 3 2 5
On vancomycin prior to study enrolment 5 7 12
Duration of vancomycin treatment prior to enrolment, days (median, IQR) 3 (3, 5) 4 (3, 5) 3.5 (3, 5)
On daptomycin prior to study enrolment 0 0 0
Diagnosis at enrolment    
Uncomplicated bacteremia 7 5 12
Complicated bacteremia without endocarditis 0 2 2
Endocarditis 0 0 0
Vancomycin MIC (median, IQR) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5) 1.5 (1.5, 1.5)
  1. Data are number of cases, unless otherwise stated
  2. Abbreviations: CKD chronic kidney disease, MIC minimum inhibitory concentration, IQR interquartile range